Veru Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Veru han disminuido a una tasa media anual de -51.6%, mientras que en la industria Personal Products los beneficios crecieron en un 12% anualmente. Los ingresos han ido disminuyendo a una tasa media de 2.6% al año.

Información clave

-51.6%

Tasa de crecimiento de los beneficios

-44.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Personal Products	20.9%
Tasa de crecimiento de los ingresos	-2.6%
Rentabilidad financiera	-121.5%
Margen neto	-393.7%
Próxima actualización de resultados	08 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Jan 09

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

Aug 16

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Apr 17

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

Feb 14

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Aug 03

Veru eligible for expedited review in U.K. for COVID-19 therapy

Jul 25

Veru: The Signs Seem To Point To An EUA For Sabizabulin

Jul 13

Veru phase 3 results of sabizabulin for COVID-19 published in NEJM

Jul 06

Veru: On Right Track For FDA EUA Submission

May 27

Is Veru (NASDAQ:VERU) Using Debt Sensibly?

May 25

Veru: Where Big Pharma Failed To Tread

May 17

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Veru. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:VERU Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	16	-63	51	32
30 Sep 23	16	-93	52	51
30 Jun 23	15	-125	55	74
31 Mar 23	21	-141	55	89
31 Dec 22	28	-116	46	81
30 Sep 22	39	-84	43	71
30 Jun 22	52	-47	31	52
31 Mar 22	60	-28	26	45
31 Dec 21	61	-16	23	37
30 Sep 21	61	7	21	33
30 Jun 21	57	0	19	28
31 Mar 21	50	0	17	21
31 Dec 20	47	2	16	17
30 Sep 20	43	-19	15	17
30 Jun 20	40	-10	15	17
31 Mar 20	39	-10	15	18
31 Dec 19	36	-13	15	17
30 Sep 19	32	-12	14	14
30 Jun 19	28	-17	15	13
31 Mar 19	24	-22	15	12
31 Dec 18	20	-22	15	11
30 Sep 18	16	-24	15	11
30 Jun 18	14	-21	14	9
31 Mar 18	13	-14	13	6
31 Dec 17	13	-11	12	5
30 Sep 17	14	-9	12	3
30 Jun 17	14	-6	10	2
31 Mar 17	15	-4	8	1
31 Dec 16	17	-3	8	0
30 Sep 16	22	0	9	0
30 Jun 16	26	3	10	0
31 Mar 16	28	3	12	0
31 Dec 15	34	5	13	0
30 Sep 15	33	4	12	0
30 Jun 15	31	3	12	0
31 Mar 15	31	3	11	0
31 Dec 14	24	2	9	0
30 Sep 14	24	2	9	0
30 Jun 14	24	10	6	0
31 Mar 14	23	9	7	0
31 Dec 13	28	12	7	0
30 Sep 13	31	14	8	0
30 Jun 13	37	16	10	0

Ingresos de calidad: VERU actualmente no es rentable.

Margen de beneficios creciente: VERU actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: VERU no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 51.6% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de VERU en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: VERU no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Personal Products (3.4%).

Rentabilidad financiera

Alta ROE: VERU tiene una rentabilidad financiera negativa (-121.54%), ya que actualmente no es rentable.

Veru Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Consensus revenue estimates decrease by 32%, EPS upgraded

The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

Consensus revenue estimates decrease by 44%, EPS upgraded

Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Consensus revenue estimates increase by 12%

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors

Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Consensus revenue estimates fall by 60%

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$25.60

Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically

Price target decreased to US$25.60

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?

Veru FDA AdCom meeting for COVID-19 therapy postponed

Veru: A Good Combination Of A Stable Business And Growth Opportunities

Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy

Veru Inc. Receives Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

Veru Inc. Appoints Jason Davies as Executive Vice President General Manager of Europe, the Middle East and Africa, Latin America, and Asia Pacific

Consensus revenue estimates fall by 25%

Independent Director exercised options and sold US$1.8m worth of stock

Veru sheds 13% to end rally as director sells shares

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Veru Q3 2022 Earnings Preview

Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer

Veru Inc. to Report Q3, 2022 Results on Aug 11, 2022

Uk’S Medicines and Healthcare Products Regulatory Agency (Mhra) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized Covid-19 Patients of Veru Inc

Veru eligible for expedited review in U.K. for COVID-19 therapy

Veru: The Signs Seem To Point To An EUA For Sabizabulin

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating That Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized Covid-19 Patients

Desglose de ingresos y gastos
Beta